<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254785</url>
  </required_header>
  <id_info>
    <org_study_id>OZM-054</org_study_id>
    <nct_id>NCT02254785</nct_id>
  </id_info>
  <brief_title>Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer</brief_title>
  <official_title>A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ozmosis Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the clinical benefit rate in patients with
      metastatic castrate-resistant prostate cancer and poor prognostic factors treated with
      cabazitaxel or novel hormonal agents (abiraterone or enzalutamide) as initial therapy, to
      determine which treatment is most active in this population. Clinical benefit rate is defined
      as PSA or measurable radiological response of any duration or stable disease for &gt; or equal
      to 12 weeks, in the absence of other indicators of progression.

      There is option to cross-over onto the other arm if the patient progresses.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>12 weeks or more</time_frame>
    <description>To assess and compare the clinical benefit rate in patients with mCRPC and poor prognostic factors treated with cabazitaxel or novel hormonal agents (abiraterone or enzalutamide) as initial therapy, to determine which treatment is most active in this population. Clinical benefit rate is defined as PSA or measurable radiological response of any duration or stable disease for greater than or equal to 12 weeks, in the absence of other indicators of progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment time to progression</measure>
    <time_frame>12 weeks until disease progression</time_frame>
    <description>To measure the treatment time before any type of progression (symptomatic, PSA, or radiological) between Arm A and Arm B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 weeks until disease progression</time_frame>
    <description>To measure the progression-free survival of metastatic castration-resistant prostate cancer patients following treatment with cabazitaxel or abiraterone/enzalutamide as initial therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 weeks until 2 years after last study visit</time_frame>
    <description>To measure the overall survival of metastatic castration-resistant prostate cancer patients following treatment with cabazitaxel or abiraterone/enzalutamide as initial therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Metastatic Castration-Resistant Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone or enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabazitaxel</intervention_name>
    <description>Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone 1000mg daily (oral) until disease progression</description>
    <arm_group_label>Abiraterone or enzalutamide</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide 160mg daily (oral)</intervention_name>
    <description>Enzalutamide 160mg daily (oral) until disease progression</description>
    <arm_group_label>Abiraterone or enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of prostate adenocarcinoma.

          -  Able and willing to provide informed consent and to comply with the study procedures

          -  Age ≥18

          -  Evidence of metastatic disease on a chest, abdominal, or pelvic CT scan and/or bone
             scan within 6 weeks of registration

          -  Castration resistant disease defined as evidence of radiological and/or PSA
             progression despite castrate levels of testosterone (serum testosterone &lt; 50 ng/dL
             (1.7 nmol/L)). For PSA progression, there must be at least 2 sequential rises at a
             minimum of 1-week intervals. The first PSA value must be ≥ 2. (Prostate Cancer Working
             Group 2 (PCWG2) criteria)

          -  Poor prognosis disease as defined by any of the following:

        the presence of liver metastases OR development of castration-resistance within 12 months
        of orchiectomy or commencement of LHRH antagonist/agonist for metastatic disease OR the
        presence of 4 or more of the following factors:

          -  LDH &gt; ULN

          -  ECOG Performance status (PS) 2

          -  visceral metastatic disease

          -  serum albumin less than or equal to 4 g/dL

          -  ALP &gt; ULN

          -  or &lt; 36 months from commencement of initial androgen deprivation therapy to study
             enrollment

          -  ECOG PS 0-2.

          -  Adequate end-organ function within 14 days of registration:

        Haemoglobin ≥ 90 g/L Neutrophils ≥ 1.5 x 109 /L Platelets ≥ 100 x 109/L AST &lt; 1.5 x ULN ALT
        &lt; 1.5 x ULN Bilirubin ≤ 1.0 x ULN (exceptions for Gilbert's syndrome) Creatinine ≤ 1.5 x
        ULN

          -  At least 21 days have passed since completing radiotherapy (exception for
             radiotherapy: at least 7 days since completing a single fraction of ≤ 800 cGy to a
             restricted field or limited-field radiotherapy to non-marrow bearing area such as an
             extremity or orbit) at the time of randomization.

          -  At least 21 days have passed since receiving any investigational agent at the time of
             registration.

          -  At least 21 days have passed since major surgery.

          -  Neuropathy ≤ grade 1 at the time of registration.

          -  Has recovered from all therapy-related toxicity to ≤ grade 2 (except alopecia, anemia
             and any signs or symptoms of androgen deprivation therapy) at the time of
             registration.

          -  Eligible for abiraterone acetate and/or enzalutamide as per standard of care
             practices.

        Exclusion Criteria:

          -  Histologic evidence of small cell/neuroendocrine prostate cancer.

          -  Other chemotherapy regimen beyond one prior course of docetaxel.

          -  Previously received treatment with cabazitaxel.

          -  Received any prior next-generation anti-androgen (e.g. enzalutamide, ARN-509) or CYP
             17 inhibitors (e.g. abiraterone, TAK-700).

          -  Other condition, illness, psychiatric condition, or laboratory abnormality that may
             increase the risk associated with administration of cabazitaxel, abiraterone or
             enzalutamide, study participation, or may interfere with the interpretation of study
             results and in the judgment of the investigator would make the patient inappropriate
             for entry into this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim N Chi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health-Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Cantre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Kelowna</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5J3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA- Vancouver Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Regional Cancer Centre (Lakeridge Health)</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Center</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>27N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>poor prognosis</keyword>
  <keyword>castrate-resistant prostate cancer</keyword>
  <keyword>cabazitaxel</keyword>
  <keyword>abiraterone</keyword>
  <keyword>enzalutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

